Table 1 The levels of serum biomarkers of the participants according to glucose tolerance state in year 2008.

From: Serum biomarkers from cell-based assays for AhRL and MIS strongly predicted the future development of diabetes in a large community-based prospective study in Korea

 

Gender (n)

NGT mean (±SD)

IGT mean (±SD)

Diabetes mean (±SD)

p value*

Post hoc (Tukey)

N

Total (1,537)

919

244

374

  

Male (687)

399

104

184

  

Female (850)

520

140

190

  

AhRL (pM, TCDDeq)

Total

1.72 (0.97)

3.18 (1.43)

4.74 (1.85)

<0.001

a,b,c

Male

1.74 (0.98)

3.21 (1.41)

4.75 (1.75)

<0.001

a,b,c

Female

1.70 (0.97)

3.17 (1.46)

4.73 (1.94)

<0.001

a,b,c

MIS-ATP (% Control)

Total

94.3 (11.6)

83.2 (9.6)

80.4 (10.6)

<0.001

a,b,c

Male

94.6 (11.5)

82.7 (9.9)

80.4 (10.8)

<0.001

a,b

Female

94.1 (11.6)

83.6 (9.4)

80.4 (10.5)

<0.001

a,b,c

MIS-ROS (% Control)

Total

109.7 (9.3)

122.1 (15.0)

127.3 (19.6)

<0.001

a,b,c

Male

109.5 (9.4)

122.9 (14.7)

128.5 (19.2)

<0.001

a,b,c

Female

109.9 (9.3)

121.5 (15.2)

126.0 (19.9)

<0.001

a,b,c

  1. In post hoc analysis, each lower-case letter in the last column represents a pair with a significant difference; ‘a’ for NGT and IGT; ‘b’ for NGT and DM; ‘c’ for IGT and DM. AhRL is expressed as 2,3,7,8-tetrachlorodibenzodioxin (TCDD) equivalents (TCDDeq, pM). MIS-ATP and MIS-ROS are expressed as % of the 10% charcoal-stripped human serum (CSS)-treated control. *p values were calculated by one-way analysis of variance, with Tukey’s post hoc test used to determine differences among the groups.